Abstract:Inherited retinal diseases are a group of progressive blinding disorders caused by genetic defects, characterized by marked genotypic and phenotypic heterogeneity. With the continuous expansion of disease-causing gene spectra, improvements in vector engineering, and rapid progress in translational studies, gene therapy has emerged as one of the most promising precision treatment strategies for these conditions. In recent years, adeno-associated virus(AAV)-based gene augmentation therapy has achieved the most significant clinical progress, and the approval of voretigene neparvovec(Luxturna)represents a landmark in retinal gene therapy. Meanwhile, gene editing and mutation-independent approaches, including optogenetic therapy are providing new options for dominant inherited disorders, diseases caused by large gene deletions or duplications, and patients at advanced stages. Despite these advances, several barriers continue to hinder broader clinical application, including limited vector capacity, immune responses, the need to optimize delivery routes, challenges in identifying therapeutic windows, and limited cost accessibility. This article reviews the primary technologies for gene therapy of inherited retinal diseases, optimization of delivery systems, clinical progress in representative diseases, and current challenges, and provides a perspective on future development directions.